FLT3 and acute myeloid leukemia: Two types of activating FLT3 mutations, namely FLT3-ITD (an internal tandem duplication mutation in the juxtamembrane domain) and FLT3-KDM (a missense mutation at the Asp835 residue within the kinase domain), account for ∼30% of AML patients (Nakao et al, 1996; Kiyoi et al, 1998; Yamamoto et al, 2001; Gilliland and Griffin, 2002a, 2002b).